Navigation Links
iBio Adds New Therapeutic Antibody to Its Pipeline
Date:3/4/2013

NEWARK, Del., March 4, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO)  announced it is proceeding with development of an antibody candidate as a therapeutic against influenza, including highly pathogenic H5N1 strains resistant to drugs such as oseltamivir (marketed as Tamiflu®). This proprietary antibody, which is based upon iBio's iBioLaunch™ technology,  has demonstrated safety and therapeutic efficacy in highly predictive animal models infected with a variety of influenza types, including H5N1.

(Logo:  http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

The influenza antibody was discovered by scientists at Fraunhofer USA Center for Molecular  Biotechnology (Fraunhofer) and is a part of Bio's successful antibody research collaboration with Fraunhofer.  Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates.

"We are pleased to further expand our antibody product candidate pipeline, particularly with an important proprietary candidate," said Robert Kay , Chairman and CEO of iBio. "This development continues our strategy to grant royalty-bearing licenses of iBioLaunch technology to others for development of their products using our platform, as we recently announced with Caliber Biotherapeutics for their anti-cancer monoclonal antibody candidate, while we continue to bring forward our own product candidates for self-development and eventual partnership with others."

About the iBioLaunch™ Platform

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with prot
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
2. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
3. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. United Therapeutics Announces Additional $420 Million Share Repurchase Program
6. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
7. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Shield Therapeutics Selects OpenClinica Enterprise
10. Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... ANY LAB TEST NOW(R), the first retail direct-access ... partnered with Atherotech, Inc., a Birmingham, Alabama-based CLIA-laboratory to ... an affordable price. The VAP Cholesterol Test is an ... people at risk and is the first cholesterol test ...
... Belgium, May 14 , - ... Accordance With the Law of May 2, 2007 , ... company,focused on the discovery and development of innovative treatments for ... update for,the three month period ending 31 March, 2009. , ...
... Histology, Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... in a Phase 2 clinical trial of its lead ...
Cached Biology Technology:VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 2VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R) 3ThromboGenics NV: Business Update 2ThromboGenics NV: Business Update 3ThromboGenics NV: Business Update 4ThromboGenics NV: Business Update 5ThromboGenics NV: Business Update 6ThromboGenics NV: Business Update 7VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
(Date:7/10/2014)... New research from The University of Texas Health ... GameKeep it Real (IYG), a health education program designed ... can significantly reduce dating violence behaviors among minority youth. ... Prevention, 10 percent of high school youth are victims ... more than 20 percent are victims of emotional dating ...
(Date:7/10/2014)... predict that western Lake Erie will have a significant ... 2014 bloom season in late summer. However, the predicted ... intense bloom, and considerably less than the record-setting 2011 ... western basin and are classified by an estimate of ... , Harmful algal blooms (HABs) were common in western ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3
... team of Duke Medicine researchers has engineered cartilage from induced ... use in tissue repair and studies into cartilage injury and ... in the journal the Proceedings of the National Academy ... or iPSCs, may be a viable source of patient-specific articular ...
... The Journal of Cell Biology shows how ... nerve cells to help prevent neurodegeneration. The findings could pave ... in patients with neurodegenerative diseases. In Lou Gehrig,s ... in stages, with axons deteriorating first and the cells themselves ...
... who have lost a substantial amount of weight after ... their siblings who were born before the weight loss ... weight loss that occur after the surgery have a ... according to a new study presented at the Canadian ...
Cached Biology News:Duke researchers engineer cartilage from pluripotent stem cells 2Stay-at-home transcription factor prevents neurodegeneration 2Obese moms give birth to heart healthier kids following bariatric surgery 2Obese moms give birth to heart healthier kids following bariatric surgery 3
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: